New study raises questions about early-stage cancer therapies for children
The bar for clinical trials involving children, by design, is set higher than it is for adults. Before a drug can be given to children in a Phase 1 trial, it must have already been tested in adults and shown some signals about its safety and clinical promise.
That, however, does not mean the outcomes will be any better, according to a new study.
Scientists conducted a systematic review and meta-analysis of Phase 1 clinical trials involving children with cancer and found, on average, only 1 in 10 will see their condition
